Fenchol, a natural compound abundant in some plants including basil, can help protect the brain against Alzheimer’s disease pathology, a preclinical study led by University of South Florida… read more.
A Hebrew SeniorLife study published in the Journal of the American Geriatrics Society provides a framework to better understand risk factors for developing delirium, a common psychiatric syndrome… read more.
Insomnia may be a potential risk factor for a brain bleed from a ruptured aneurysm along with more well known risk factors of smoking and high blood pressure,… read more.
Alzheimer’s disease is known for its slow attack on neurons crucial to memory and cognition. But why are these particular neurons in aging brains so susceptible to the… read more.
Since 1949, lithium has been a mainstay for treating bipolar disorder (BD), a mental health condition marked by extreme mood swings. But scientists still don’t have a clear… read more.
Mirtazapine, an antidepressant often used to treat agitation in patients with dementia, is ineffective, researchers reported on Oct. 21, 2021 in The Lancet. And the investigators found a… read more.
Certain microRNAs indicate risk for cognitive decline DZNE – German Center for Neurodegenerative Diseases Researchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules… read more.
Menopausal hormone therapy (MHT — also known as hormone replacement therapy, HRT) does not appear to increase the risk of dementia onset, researchers reported on Sept. 29, 2021… read more.
Over 50 million people around the world suffer from dementia. Alzheimer’s disease is the most common form of dementia and is characterised by an accumulation of the proteins… read more.
Researchers at Uppsala University have designed new antibodies that might provide more effective treatment methods for Alzheimer’s disease. By designing antibodies that bind even to the smaller aggregates,… read more.
Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and schizophrenia. Current treatment options for memory loss are very limited and… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
